
A retrospective study finds that direct selective laser trabeculoplasty significantly lowers intraocular pressure, with the greatest benefit seen in treatment-naive eyes.
The FDA has approved Refocus Group's request to begin phase II clinical trials of its scleral implants and scleral spacing procedure for the surgical treatment of presbyopia.




